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Background: Traditional endpoints in oncology are based on measuring the tumor size and 
combining this with a time factor. Current studies with immunotherapy show that even when 
median survival is unaltered, a significant proportion of patients can achieve prolonged survival. 
Objective tumor response does not always mean “overall” improvement, especially if toxicity is 
harsh. Novel agents are significantly expensive, and it is therefore crucial to measure the impact 
on “quality” of life, in addition to “quantity”.
Materials and methods: We studied the preferences and experiences of cancer patients and 
their caregivers, measuring subjective well-being (SWB) ratings, EQ5D descriptions and time 
trade-off preferences.
Results: We studied 99 patients and 88 caregivers. Life satisfaction ratings were similar between 
the two groups, but daily mood was significantly lower in caregivers (P<0.1). Anxiety/depression 
affected SWB, while pain and mobility did not. Positive thoughts about health were associated 
with better daily moods in both groups, and stage IV cancer was associated with lower life 
satisfaction. Cancer in remission was associated with better daily moods, but, interestingly, not 
with patient life satisfaction. Patients with better daily mood and positive thoughts about family 
were less willing to “trade-off ” life years.
Conclusion: Caregivers are as anxious or depressed as patients, and report similar levels of 
life satisfaction but lower daily mood. A focus on SWB could provide a valid assessment of 
treatment benefit. Given the interesting results of this pilot study, we suggest a larger study 
should be conducted, measuring SWB over time.
Keywords: subjective well-being, EQ5D, TTO, life satisfaction, day affect
Introduction
Traditional endpoints in oncology are mainly based on objective measurement of tumor 
size combined with a time factor. Both the oncology community and the regulatory 
authorities rely heavily upon these endpoints to judge the benefit of new therapies. 
However, time-dependent variables such as median survival can be difficult to explain 
to patients and they lack individualization. Despite the widely accepted opinion that 
patients will accept any amount of additional time at any cost, this is not always the 
case. For patients, and their caregivers, quality and quantity of additional time go 
hand-in-hand, and even a modest gain in overall survival accompanied by significant 
toxicity might not be considered acceptable.
The question then is how do we reliably measure benefit and symptoms? And 
what could we do to make clinical endpoints more meaningful to individual patients?
Increasingly, “softer” measures of efficacy, such as symptom scores and Quality of 
Life (QoL) questionnaires, are being integrated into drug development process. Maisey 
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et al demonstrated that patients with a higher baseline QoL 
do better.1,2 Quinten et al published a meta-analysis of 30 
European Organisation for Research and Treatment of Cancer 
(EORTC) studies which demonstrated that QoL measures 
were statistically much more reliable than Eastern Cooperative 
Oncology Group performance status.3 With regards to symp-
toms assessment, Vera-Badillo et al analyzed 164 trials and 
demonstrated that symptoms and toxicity are poorly reported.4 
Clinicians often rely on Common Terminology Criteria (CTC) 
grading to report toxicity, and although CTC provides a com-
mon language among physicians, it is often based on arbitrary 
cut-offs. The National Cancer Institute and the US Food and 
Drug Administration are now considering assessing common 
symptoms such as fatigue, nausea and diarrhea, directly from 
the patient rather the clinician, in view of mounting evidence 
that this method results in better symptom reporting.
While publicly funded health care aims to improve 
patients’ health, it also requires that, ideally, the benefits of 
treatments should be compared to one another using a com-
mon currency. The currency most often considered is the 
Quality-Adjusted Life Year (QALY). The Q in the QALY 
is calibrated on a scale between 0 (for dead) and 1 (for full 
health). QALY calculations rely on the ability to describe 
the most important experiences of health, and generic health 
state descriptive systems, such as the EQ5D and  Six-Form 
6-Dimension (SF6D), have been devised in order to allow 
individuals to describe their current health by answering a 
number of questions.5,6 QALYs then require that those states 
are valued. The National Institute of Clinical Excellence 
favors using the hypothetical preferences of members of 
the general public, who are asked to consider sacrifices in 
terms of risk of death (standard gamble) or length of life 
(time trade-off [TTO]) for improvements in QoL.7 There 
are limitations in this approach; firstly, in describing health 
in terms of a fixed and deliberately simplified descriptive 
system, we may fail to capture what is important to people 
in terms of their health. Second, in valuing health in terms of 
hypothetical preferences, we may fail to adequately antici-
pate the real impact that different health states have on our 
lives. In continuing with the status quo, we, therefore, run 
the real risk of misallocating resources. Also, if one takes a 
real-life scenario then, for example, the person who has a 
traumatic amputation of a leg in an accident – as expected, 
the QoL declines very markedly at first, but then returns to 
near normal or even normal with time. So, the patient adapts 
and accommodates to his/her disability with time. It seems 
likely that cancer patients experience this same phenomenon 
of resetting their baseline as their disease experience unfolds.
Recently, an alternative approach which values health 
states according to their effects on reports of subjective well-
being (SWB) has been proposed. SWB is a general term for 
how we think and feel about life. The approach requires us 
to ask people very simple questions about their life satisfac-
tion (LS) or mood, to find out about their health and other 
potentially important determinants of SWB, and then to use 
regression analysis to determine the marginal effects (the hit 
on SWB) of the various determinants.
If we are to more accurately capture the benefits of cancer 
treatments and other forms of health care, we need to move 
away from EQ5D and toward a broader conception of health 
and well-being, and away from the hypothetical preferences 
of the general public and toward the real experiences of real 
patients and their families. This perspective does not require 
us to abandon the QALY approach, but it does require us 
to value the Q rather differently. A focus on SWB becomes 
further justified in light of the robust relationship between 
health and SWB8 and the positive causal relationship from 
SWB to health.9,10
So, if we know that correlation of radiologic findings and 
clinical benefit might be sometimes weak, the CTC grading 
has limitations, and that we could potentially obtain reliable 
and clinically meaningful data from our patients, then this 
raises the question, what about their nearest and dearest? 
Caregivers are often closely involved in day-to-day care, 
and at consultations, they will often prompt patients to recall 
troublesome symptoms.
With cancer becoming more of a continuous care issue 
due to increasing incidence rates, improved survival and a 
movement toward outpatient treatment, more responsibility 
overseeing patients’ care has been transferred onto their 
caregivers.11 Many studies have shown significant adverse 
effects of being a caregiver, including depression, sleep 
and appetite disorders, withdrawal from social engage-
ments12 and a reduction in time they have for themselves, 
family and friends.13 Thirty-seven percent of the intensive 
caregivers (over 20 hours per week) have mental health 
scores that are consistent with a clinical diagnosis of 
depression, which is around 10% higher than that of 
noncaregivers.14
In this study, we set out to measure the SWB score, along 
with collecting other more established standard QoL assess-
ments in a group of colorectal patients and their caregivers. 
The aim was to draw clinician’s attention in considering SWB 
as a measure of the impact of cancer on the lives of patients 
and, crucially and innovatively, on the lives of a close family 
member (henceforth “caregiver”). We undertook a pilot study 
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of the experiences of patients and their caregivers. The six 
objectives of this study were to:
1. Elicit SWB ratings from cancer patients and their 
caregivers.
2. Elicit EQ5D descriptions and TTO preferences from the 
same respondents.
3. Compare the SWB of patients and caregivers.
4. Compare the weights attached to dimensions of the EQ5D 
estimated from the various reports of SWB with those 
estimated from TTO responses.
5. Explore the relationships between SWB and the back-
ground characteristics of the respondents (including the 
EQ5D and the “cancer status” of the patient).
6. Explore the determinants of TTO values, including the 
effect of SWB measures.
Materials and methods
The study was open to recruitment between March 2010 
and December 2010 in a single tertiary cancer center. It 
was approved by the West of Scotland Research Ethics 
Committee.
The final sample consisted of 99 colorectal cancer patients 
and 88 caregivers. Given these sample sizes, we used 10% 
level of statistical significance throughout (i.e., P<0.1) and 
performed multivariable regression analysis.
The patient was asked to decide upon a family member 
who cares for his/her on a daily basis, and this person was 
asked to complete a questionnaire as a “caregiver”.
Questionnaire and coding
The questionnaire consisted of the following sections: 1) 
SWB questions, 2) TTO (patient only), 3) EQ5D, 4) EORTC 
QLQ-C30 (patient only), 5) caregiver QoL (caregiver only), 
and 6) background characteristics.
Sections (4) and (5) are very detailed measures, and 
we exclude them from our analysis because our relatively 
small samples size (n<100) means that we lack the degrees 
of freedom to generate meaningful results from regression 
analysis. We do, however, have some relevant variables about 
the disease stage and progression from (6). In any event, our 
main focus is on the relationship between (1), (2) and (3), 
within and between patients and caregivers.
The SWB questions were based on the state of the art.15 
The first question was an evaluation of overall LS: “How 
satisfied are you with your life overall? On a scale of 0 to 
100, 100 being completely satisfied and 0 so dissatisfied you 
may as well be dead”. The second question tapped into the 
experience of mood: “Overall how did you feel yesterday” 
(for each of the adjectives)? Hopeful, sad, fearful, tired, happy, 
worried, satisfied (on a 0–6 scale from “not at all” to “very 
much”). Mean day affect (DA) was calculated as the mean 
response to the positive emotion questions minus the mean 
response to the negative emotion questions.
These “headline indicators” are the main focus of our 
analyses, but they may neglect the way in which our attention 
drifts between current activities and concerns about other 
things (such as cancer). Research in psychology suggests 
such “mind wanderings” are frequent, occurring in up to 
30% of randomly sampled moments during an average day.16 
When these mind wanderings repeatedly return to the same 
issues, they are labeled as intrusive thoughts and they often 
have a negative association with our experienced utility.17,18 
Respondents were, therefore, asked separately whether they 
had thought about health and then family during the previ-
ous day and were provided with the following responses 
from which to choose: “not at all, a few times, many times 
and continually”. When the response was not “not at all”, 
patients were then asked how “happy” and “worried” they 
felt when thinking about family or health on a scale from 0 
(not at all) to 6 (very much). Responses were then coded into 
four categories in order of decreasing desirability: 1) thinking 
about health/family many times or continually with happy 
≥ worried; 2) thinking about health/family a few times with 
happy ≥ worried; 3) thinking about health/family a few times 
with happy < worried; and 4) thinking about health/family 
many times or continually with happy < worried.
In the TTO, patients (only) were asked to choose between 
10 years “with your current health problems” and varying 
amounts of time “without any health problems”, ranging 
from 0 to 10 years in intervals of 6 months. The midpoint 
between where a respondent switches his/her preferences is 
taken as his/her point of indifference, and the TTO value so 
calculated. For example, if a respondent preferred 6 years 
without problems to 10 years with problems but preferred 
10 years with problems to 5.5 years without problems, the 
TTO value =[(0.6+0.55)/2] =0.575.
For the EQ5D, respondents were asked to describe their 
health in terms of five dimensions (mobility, self-care, usual 
activities, pain, and mood), each with three levels of severity 
(1=broadly none, 2=some and 3=extreme problems). Each 
state is defined by a five-number code, from 11111 to 33333, 
and so there are 243 (35) possible states.
The background variables contained information includ-
ing disease stage, type and number of treatments, concomitant 
conditions, as well as the more “standard” variables relating 
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to age, marital status and education. Figures S1 and S2 show 
all the variables and coding used in the regression models.
Before conducting the study, potential participants who 
met the general inclusion criteria as well as cancer patient-
specific inclusion criteria were identified: 1) oncologists were 
required to confirm cancer diagnosis in the patient; and 2) 
caregivers would accompany them at their clinic visit and 
also be willing and able to complete the appropriate study 
questionnaires. Exclusion criteria were: 1) severe acute or 
chronic medical or psychiatric conditions; 2) insufficient 
ability to read and write; and 3) being unable or unwilling 
to complete the questionnaires.
All participants provided written consent by signing either 
the patient or caregiver consent form (Version 1.0, September 
2009). The Informed Consent Form explained to participants 
that anonymized study data would be stored in a computer 
database and confidentiality maintained in accordance with 
UK data legislation. Patients were instructed to designate a 
family member or caregiver on whom the patient relied for 
practical and emotional support.
To ensure a diverse sample of participants, efforts were 
made to recruit: 1) at least 30% of patients who were male 
and at least 30% who were female; 2) at least 30% of patients 
aged under 60 years; 3) at least 30% of patients in stage 1–2 
of colorectal cancer and at least 30% of patients in stage 3–4 
of colorectal cancer; and 4) a minimum of 20% of patients 
who had not completed any education (college or university) 
beyond secondary school.
Results and discussion
There was an approximately even split of male:female in the 
99 respondents in the patient group and the majority were 
Caucasian (Table 1). Caregivers were predominantly female. 
The patient group was older on average than the caregivers, 
and a larger proportion of them were retired. In terms of 
education, the patient group had largely completed less than 
a university degree: data on education were not available for 
caregivers. Patients overwhelmingly had stage III and IV 
cancer and approximately one-third of patients were classi-
fied as being in remission.
In Table 2, looking at the EQ5D, patients reported more 
physical limitations than caregivers, but, interestingly, 
reports of anxiety/depression were quite similar. Overall, 
more caregivers reported no problems on any of the dimen-
sions (40% compared to 16% of patients). The mean TTO 
score was 0.825, with around half of the patients unwilling 
to trade-off more than a year. The LS scores for patients 
and caregivers were nearly identical at 78.74 and 78.48, 
respectively, but patients had significantly higher DA: 2.36 
and 1.97, respectively.
Table 3 shows the results of patient/caregiver comparisons 
after controlling for the other variables that could significantly 
explain variation in LS and DA. There was no significant dif-
ference between patients and caregivers in LS, but caregivers 
had about a 24% lower DA score.
Table 4 shows the thoughts of patients and caregivers 
about health. Patients reported thinking more frequently and 
worrisomely about health than the caregiver group, while 
caregivers reported thinking more frequently and worri-
somely about family than the patient group.
Comparing the EQ5D scores
Regression analysis was used to determine the impact of the 
EQ5D on SWB and TTO, in a similar way to our previous 
Table 1 Background information
Patients
n=99, %
Caregivers
n=88, %
Age, years (mean)
≥60 70 46
<60 30 54
Gender
Male 52 33
Female 48 77
Ethnicity
Caucasian 97 97
Non-Caucasian 3
Employment
Full-time 17 24
Part-time 2 12
Unemployed 2 11
Retired 62 38
Other 17 15
Education
University or higher 20 N/A
Less that university 80 N/A
Cancer stage
Stage 0 2
Stage 1 0
Stage 2 11
Stage 3 30
Stage 4 53
Remission status
In remission 34
Not in remission 66
Performance status
Fully active 39
Not fully active 61
Year of diagnosis
2010 39
Pre-2010 61
Abbreviation: N/A, not available.
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work for Pfizer. Dummy variables were used to indicate some 
or extreme problems along each EQ5D dimension (mobility, 
self-care and so on).
The results are shown in Table 5. Interestingly, anxiety/
depression consistently matters to SWB, and pain and mobil-
ity consistently do not. Moderate to extreme problems with 
anxiety/depression were associated with reduction of between 
40% and 60% on the various SWB measures for patients and 
caregivers. As shown previously, there were some anomalous 
results for mobility, with “some problems walking about” 
sometimes “better” for SWB than no problems at all.
Explaining SWB and TTO
Table 6 summarizes the main regression results, which 
included additional background variables to explain each of 
the main SWB measures (LS and DA) in terms of the EQ5D, 
intrusive thoughts, and also, innovatively, in terms of the 
SWB of the other person in the pair, that is, patient SWB to 
explain caregiver SWB and vice versa.
Table 6 also shows the determinants of TTO values for 
patients only. Since the sample is relatively small, only inde-
pendent variables found to be significant (at the 10% level) 
were retained in each regression to limit the statistical noise 
created by the presence of insignificant explanatory variables.
Anxiety/depression comes through strongly for three of 
the four models, but does not appear to be related to patient 
LS, which is better explained by extreme problems with self-
care and usual activities. Patient LS scores did not appear to 
be significantly influenced by the frequency and intensity of 
thoughts about health or family. In contrast, more frequent 
and negative thoughts about health and family were associ-
ated with a roughly 25% lower DA score. Both LS and DA 
among caregivers were associated with thoughts about health, 
but not with thoughts about family.
Table 2 EQ5D questionnaire responses for patients and caregivers
Answers Mobility, % Self-care, % Usual activities, % Pain/distress, % Anxiety/depression, %
EQ5D patients
Level 1 48 84 43 40 54
Level 2 52 14 50 51 41
Level 3 0 2 7 9 5
11111 16
EQ5D carers 
Level 1 87 94 85 63 55
Level 2 17 6 15 31 41
Level 3 0 0 0 6 4
11111 40
Notes: For the EQ5D, respondents were asked to describe their health in terms of five dimensions (mobility, self-care, usual activities, pain, and mood), each with three 
levels of severity (1=broadly none, 2=some and 3=extreme problems).
Table 3 Patient–caregiver comparisons (only significant variables shown)
Life satisfaction Day affect
Mean day affect 0.606
Life satisfaction 0.611
Problems with usual activities –0.155
Frequency and intensity of thoughts around health –0.265
Frequency and intensity of thoughts around family 0.133
Having at least one EQ5D dimension at level 3 –0.191
Responder being a caregiver –0.039 (not significant) –0.241
Table 4 Intrusive thoughts
Patient, % Caregiver, %
Thoughts around health
Many times, “happy” rated greater than or equal to “worried” 15.0 15.0
A few times, “happy” rated greater than or equal to “worried” 52.5 67.5
A few times, “worried” rated greater than “happy” 8.8 15.0
Many times, “worried” rated greater than “happy” 23.8 2.5
Thoughts around family
Many times, “happy” rated greater than or equal to “worried” 56.5 49.4
A few times, “happy” rated greater than or equal to “worried” 29.3 29.1
A few times, “worried” rated greater than “happy” 5.4 3.8
Many times, “worried” rated greater than “happy” 8.7 17.7
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Being a stage IV cancer patient, a group comprising 
over half the study’s patient population, was found to have 
a negative effect on the LS of both patients and caregivers, 
with an associated reduction of 6% and 14%, respectively. 
Interestingly, patient LS was found to be negatively affected 
by cancer going into remission, with an associated 15% 
reduction in LS. Being in remission was good for patient 
DA (and caregiver DA too), with increases of 15% and 18%, 
respectively.
Table 6 also shows the significant association found 
between LS and DA within both patients and caregivers, 
and also some relationship across the groups. Patient LS 
was significantly affected by caregiver LS scores. Caregiver 
LS was associated with patient DA scores, although in the 
unexpected direction, with higher caregiver LS being associ-
ated with lower patient DA.
Age, gender, marital status, employment and education 
data were not found to be significant in predicting SWB 
scores.
Unsurprisingly, TTO values were explained by extreme 
pain/discomfort and by extreme anxiety/depression. More 
innovatively, TTO values were not explained by thoughts 
about health, but by thoughts about family – the better those 
thoughts were, the lesser the willingness to give up life years 
to avoid current health problems. A further novel finding is 
that better DA of both patient and caregiver was associated 
with less willingness to give up life years.
Conclusion and recommendations
In principle, there is no doubt that QALYs are a powerful 
tool for allocating health care resources. In practice, there are 
problems with how the Q in the QALY is generated, that is, 
Table 5 EQ5D “tariff” models
 LS patient DA patient LS caregiver DA caregiver TTO patient
Constant 86.62 3.62 88.06 3.08
−0.134
Mobility 2
−0.022 0.024 −0.089 0.119 0.109
Mobility 3 N/A N/A N/A N/A N/A
Self-care 2
−0.157 −0.129 −0.084 −0.201* 0.078
Self-care 3
−0.108 −0.007 N/A N/A −0.013
Usual activities 2
−0.170 −0.182* −0.190 −0.169 −0.052
Usual activities 3
−0.347* −0.363* N/A N/A 0.010
Pain/distress 2 0.041 0.002
−0.033 0.009 0.010
Pain/distress 3
−0.146 −0.288 0.274 −0.081 −0.450*
Anxiety/depression 2
−0.133 −0.235* −0.410* −0.487* −0.167*
Anxiety/depression 3
−0.441* −0.459* −0.464* −0.641* −0.233*
Any 3 0.427* 0.347
−0.184 −0.378 0.050
R2 0.160 0.286 0.472 0.358 0.199
Notes: Significance at 10% in bold and asterisk. For each parameter, levels of severity are 1: broadly none, 2: some, and 3: extreme problems.
Abbreviations: LS, life satisfaction; DA, day affect; TTO, time trade-off; N/A, not available. 
Table 6 Summary of regression results (only significant variables shown)
LS patient DA Patient LS caregiver DA caregiver TTO patient
Self-care 3
−0.204
Usual activities 3
−0.238
Pain/distress 3
−0.204
Anxiety/depression 2
−0.192 −0.232 −0.323
Anxiety/depression 3
−0.206 −0.379 −0.353 −0.206
Any 3
−0.347
Thoughts: health
−0.219 0.242 −0.326
Thoughts: family
−0.236 0.376
LS patient 0.540 0.251
DA patient 0.741 0.315
LS caregiver 0.196
−0.169 0.387
DA caregiver 0.392 0.205
Cancer stage IV
−0.061 −0.144
Cancer in remission
−0.152 0.154 0.182
R2 0.582 0.684 0.625 0.730 0.460
Abbreviations: LS, life satisfaction; DA, Day affect; TTO, time trade-off.
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with how health is described and valued. Descriptive systems, 
such as the EQ5D, are not really designed to pick up the impact 
of conditions on non-patient populations such as caregivers.
This is one of the few studies that have elicited SWB 
ratings (and TTO values) from a clinical population. The 
study focuses on patients with colorectal cancer and their 
caregivers. It is best described as a pilot study involving 99 
patients and 88 caregivers, and our data allow us to directly 
compare the SWB of these two groups (objective 3). The first 
thing to note is that caregivers are just as anxious or depressed 
as patients and, at face value, this highlights the potential 
importance of support being available to families of cancer 
patients as well as to the patients themselves.
The LS scores for patients and caregivers were nearly iden-
tical, but patients had significantly higher DA. These results 
potentially further demonstrate that caregivers are significantly 
impacted by cancer and are potential beneficiaries of treatment. 
Although patients reported worse health on the EQ5D (with 
only 16% in 11111 as compared to 40% of caregivers, with 
“11111” indicating “broadly no” problems in the five EQ5D 
dimensions), the proportions reporting problems with anxiety/
depression are the same across the two groups and, from this 
and other work, it is strongly suggested that anxiety/depres-
sion does the “heavy lifting” in SWB. Both caregiver LS and 
caregiver DA are strongly associated with anxiety/depression.
The results in Table 5 confirm previous analyses, which 
basically show that mental health is the most important 
dimension for SWB and pain/discomfort is additionally 
important for TTO. The sample sizes are small, and we should 
be cautious about making inferences about what does not 
affect SWB, but very few dimensions and levels of the EQ5D 
are significant in explaining LS and DA. We might need to 
face up to the fact that limitations to mobility, for example, 
really do not significantly affect our SWB.
We have discussed the importance of mental health as the 
major determinant of SWB in a previous work supported by 
Pfizer. This highlights that treatments that bring about reduc-
tion in anxiety or depression (or other psychiatric symptoms) 
are equally important. From studies in the general population, 
we know that the importance of mental health was strongest 
for LS, but here the impact is broadly comparable across both 
the main measures of SWB.
In exploring the relationships between SWB and the 
background characteristics of the respondents (objective 5), 
the results for patient LS suggest some interesting findings 
more generally. In particular, being in remission is associated 
with lower LS. This seems counterintuitive, since remission 
involves the prospect of better health and a longer life. It 
could be, however, that active cancer allows people to make 
sense of their lives and find meaning in the face of adversity. 
On the other hand, being in remission is good for the DA of 
both patients and caregivers. Cancer in stage IV was associ-
ated with a significant reduction in caregiver LS and cancer 
being in remission was good for the DA of caregivers.
It is also worth noting the role thoughts about health and 
family play in explaining differences between the two main 
SWB measures. Such thoughts do not seem to affect LS as 
much as they affect DA (especially for patients). This might 
suggest that DA might be failing to capture some important 
effects on SWB that result from mind wanderings.16
By eliciting TTO values from patients, we were able to 
explore the impact of SWB on these values, as well as to 
look for effects of the usual suspects relating to the EQ5D 
(objective 6). The pain and mood dimensions of the EQ5D 
affect TTO values. While thoughts about health do not appear 
to affect TTO values,19 those who have more thoughts about 
their family are less willing to trade-off life years, and this 
makes good sense. Better DA of both patient and caregiver 
also results in greater reluctance to give up life years.
It is noteworthy that none of the “standard” background 
variables (age, gender, education and so on) had much effect 
on SWB and TTO. Of course, with larger sample sizes, some 
of these effects may have been significant, so we should be 
cautious about claiming such factors do not matter. Indeed, 
the burgeoning literature on SWB suggests that many of these 
background variables are indeed important determinants of 
SWB.20 Perhaps another important factor in patients’ QoL that 
was not included in our study is the use of complementary 
and alternative medicines. Given the increasingly evolving 
evidence on the impact of complementary medicine in cancer 
patients’ QoL, it is worth considering adding questions on 
their use in future questionnaires.21
This pilot study has provided some useful insights into 
the SWB of cancer patients and their caregivers, and we now 
need larger, longitudinal studies that more closely monitor the 
impact of cancer on patients and caregivers. Such research 
would begin to shed light on how different cancer and health 
states causally affect SWB and how SWB causally affects 
cancer and health states. There is some good evidence on the 
causal effects that SWB has on a range of outcomes, including 
health,22 and so it may be that effective interventions in health 
care might be those that seek to improve SWB.
Some of the results from this pilot study have been 
surprising. Firstly, the finding that LS is lower for patients 
who are in remission is a particularly noteworthy finding 
that requires further investigation into the degree to which it 
reflects a “genuine effect” and the degree to which it reflects 
some kind of cognitive dissonance on the part of patients.
 
Pa
tie
nt
 R
el
at
ed
 O
ut
co
m
e 
M
ea
su
re
s 
do
wn
lo
ad
ed
 fr
om
 h
ttp
s:
//w
ww
.d
ov
ep
re
ss
.c
om
/ b
y 
13
0.
20
9.
11
5.
82
 o
n 
08
-N
ov
-2
01
7
Fo
r p
er
so
na
l u
se
 o
nl
y.
Powered by TCPDF (www.tcpdf.org)
                               1 / 1
Patient Related Outcome Measures 2017:8submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
118
Graham et al
While anxiety/depression emerged as an important deter-
minant of SWB, its greater effect on DA relative to LS in this 
study is slightly at odds with what we found in the previous 
work with the general population; further research should 
explore the reason for these differences.
The fact that pain matters greatly in TTO preferences but 
hardly shows up at all in SWB is intriguing, and we need 
to examine the robustness of this difference more fully. As 
shown before, pain relief would be less cost-effective using 
an SWB-based approach.23
This study provides insights on the determinants of 
well-being in cancer patients and their caregivers and the 
real-world benefits of treatment. Our future work will build 
on the pilot study reported here.
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